215 related articles for article (PubMed ID: 33453149)
1. The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
Cavaleri M; Enzmann H; Straus S; Cooke E
Lancet; 2021 Jan; 397(10272):355-357. PubMed ID: 33453149
[No Abstract] [Full Text] [Related]
2. The Conditional Marketing Authorisation of Covid-19 Vaccines: A Critical Assessment under EU Law.
Donati A
Eur J Health Law; 2022 Mar; 29(1):33-52. PubMed ID: 35303726
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines approved in the European Union: current evidence and perspectives.
Bellino S
Expert Rev Vaccines; 2021 Oct; 20(10):1195-1199. PubMed ID: 34338126
[No Abstract] [Full Text] [Related]
4. von der Leyen admits to COVID-19 vaccine failures.
Hyde R
Lancet; 2021 Feb; 397(10275):655-656. PubMed ID: 33610198
[No Abstract] [Full Text] [Related]
5. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
Manellari S; Musazzi UM; Rocco P; Minghetti P
Int J Pharm; 2023 Jul; 642():123193. PubMed ID: 37394157
[TBL] [Abstract][Full Text] [Related]
6. Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
Shivji R; Conocchia R; Korakianiti E; Jekerle V
Vaccine; 2022 Sep; 40(38):5539-5541. PubMed ID: 35779964
[TBL] [Abstract][Full Text] [Related]
7. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
8. Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation).
Raposo VL
Eur J Health Law; 2021 Apr; 28(2):165-183. PubMed ID: 33878713
[TBL] [Abstract][Full Text] [Related]
9. Reporting of AstraZeneca studies may have caused vaccine reservations.
Bignardi G
BMJ; 2021 Apr; 373():n937. PubMed ID: 33846122
[No Abstract] [Full Text] [Related]
10. Market design to accelerate COVID-19 vaccine supply.
Castillo JC; Ahuja A; Athey S; Baker A; Budish E; Chipty T; Glennerster R; Kominers SD; Kremer M; Larson G; Lee J; Prendergast C; Snyder CM; Tabarrok A; Tan BJ; Więcek W
Science; 2021 Mar; 371(6534):1107-1109. PubMed ID: 33632897
[No Abstract] [Full Text] [Related]
11. Beyond Politics - Promoting Covid-19 Vaccination in the United States.
Wood S; Schulman K
N Engl J Med; 2021 Feb; 384(7):e23. PubMed ID: 33406324
[No Abstract] [Full Text] [Related]
12. Temporary derogation from European environmental legislation for clinical trials of genetically modified organisms for coronavirus disease 2019.
Iglesias-Lopez C
Cytotherapy; 2021 Jan; 23(1):10-11. PubMed ID: 33082093
[TBL] [Abstract][Full Text] [Related]
13. FDA authorizes Moderna COVID-19 vaccine.
Med Lett Drugs Ther; 2021 Jan; 63(1616):9-10. PubMed ID: 33512345
[No Abstract] [Full Text] [Related]
14. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
15. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
[TBL] [Abstract][Full Text] [Related]
16. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
17. Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices.
Abed I; Gonzalez-Quevedo R; Mura M; Dias M; da Rocha Dias S; García Burgos J
Br J Clin Pharmacol; 2023 Jan; 89(1):5-10. PubMed ID: 36345231
[No Abstract] [Full Text] [Related]
18. The European Medicines Agency's goals for regulatory science to 2025.
Hines PA; Guy RH; Humphreys AJ; Papaluca-Amati M
Nat Rev Drug Discov; 2019 Jun; 18(6):403-404. PubMed ID: 31160761
[No Abstract] [Full Text] [Related]
19. Messengers of hope.
Nat Biotechnol; 2021 Jan; 39(1):1. PubMed ID: 33376248
[TBL] [Abstract][Full Text] [Related]
20. Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
Dal-Ré R; Launay O
Vaccine; 2021 Jul; 39(30):4029-4031. PubMed ID: 34120766
[No Abstract] [Full Text] [Related]
[Next] [New Search]
